Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation

Eur Heart J Suppl. 2022 Feb 14;24(Suppl A):A42-A55. doi: 10.1093/eurheartj/suab152. eCollection 2022 Feb.

Abstract

Atrial fibrillation (AF) is associated with an increased risk of stroke, which can be prevented by the use of oral anticoagulation. Although non-vitamin K antagonist oral anticoagulants (NOACs) have become the first choice for stroke prevention in the majority of patients with non-valvular AF, adherence and persistence to these medications remain suboptimal, which may translate into poor health outcomes and increased healthcare costs. Factors influencing adherence and persistence have been suggested to be patient-related, physician-related, and healthcare system-related. In this review, we discuss factors influencing patient adherence and persistence to NOACs and possible problem solving strategies, especially involving an integrated care management, aiming for the improvement in patient outcomes and treatment satisfaction.

Keywords: Adherence; Atrial fibrillation; Integrated care; Integrated management; Non-vitamin K antagonist oral anticoagulants; Oral anticoagulation; Persistence.